Document 0649 DOCN M9650649 TI Binding of distamycin and chromomycin to human immunodeficiency type 1 virus DNA: a non-radioactive automated footprinting study. DT 9605 AU Feriotto G; Mischiati C; Bianchi N; Passadore M; Gambari R; Biotechnology Centre, Ferrara University, Italy. SO Eur J Pharmacol. 1995 Jul 18;290(2):85-93. Unique Identifier : AIDSLINE MED/96171855 AB Sequence-selectivity of DNA-binding drugs was recently reported in a number of studies employing footprinting and gel retardation approaches. In this paper we studied sequence-selectivity of the binding of chromomycin and distamycin to DNA by performing DNase I footprinting and analysis of the cleaved fragments by the Pharmacia ALF DNA Sequencing System. As a model system we employed the long terminal repeat of the human immunodeficiency type 1 virus. The main conclusion of our experiments is that automated analysis of DNase I footprinting is a fast and reliable technique to study drugs-DNA interactions. The results obtained suggest that distamycin and chromomycin differentially interact with the long terminal repeat of the human immunodeficiency type 1 virus; this differential binding depends upon the DNA sequences recognized. The data presented are consistent with a preferential binding of distamycin to DNA sequences of the binding sites of nuclear factor kappa B and transcription factor IID. By contrast, distamycin exhibits only weak binding to DNA sequences recognized by the promoter-specific transcription factor Sp1. Unlike distamycin, chromomycin preferentially interacts with the binding sites of the promoter-specific transcription factor Sp1. DE Antibiotics, Antineoplastic/*METABOLISM Antiviral Agents/*METABOLISM Automation Base Sequence Chromomycins/*METABOLISM Deoxyribonucleases/METABOLISM Distamycins/*METABOLISM *DNA Footprinting DNA, Viral/*METABOLISM Fluoresceins Human HIV-1/*METABOLISM Molecular Sequence Data Polymerase Chain Reaction Support, Non-U.S. Gov't JOURNAL ARTICLE SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).